For anyone who truly has studied this drug and its mechanism of action; he or she can really appreciate the drug's true potential. Compare to other meds in similar class. Current price does not reflect it in anyway; mostly emotional trading. Many being swayed by the "shorts."
I will continue to acquire shares and hold for the broader indications to follow. Study Prostate cancer and see how many patients are actually diagnosed with it before it has progressed.This is definitely a "takeover" company. Attention "longs": hang in there. I would not be concerned about the side-effects of this drug....afterall, any patient who has been diagnosed with an end stage or terminal metastatic case.....only stands to gain. You decide which the chances you would take; suffer the possible side-effects of this drug or increase your hopes for a longer life....even if it means 6 months more plus.
Good luck to all. do your DD and not be moved easily by those attempting to short this stock.